Biofrontera Wins Key Patent Challenge Against Sun Pharma

Event summary

  • U.S. Patent Trial and Appeal Board ruled all challenged claims of Sun Pharma’s Patent 11,697,028 unpatentable on February 23, 2026.
  • Biofrontera initiated the challenge in response to Sun Pharma’s 2024 infringement allegations.
  • Sun Pharma retains the right to appeal the decision.
  • The ruling does not affect Biofrontera’s ongoing challenge against Sun Pharma’s related Patent 11,446,512.

The big picture

This ruling strengthens Biofrontera’s intellectual property position in the photodynamic therapy space, potentially reducing legal risks and allowing the company to focus more on clinical development. The outcome also highlights the strategic importance of patent challenges in the biopharmaceutical industry, where intellectual property can significantly influence market access and competitive dynamics.

What we're watching

Appeal Risk
Whether Sun Pharma will pursue an appeal that could prolong the legal battle.
Market Impact
How this ruling affects Biofrontera’s competitive position in photodynamic therapy.
Regulatory Dynamics
The pace at which the Patent Office resolves similar challenges in the biopharmaceutical sector.